Protalix BioTherapeutics, Inc. PLX NYSE

Protalix BioTherapeutics, Inc. (PLX) reported total assets of $82.35M and total liabilities of $34.12M for fiscal year 2025, resulting in total equity of $48.23M.

The company held $30.98M in cash and short-term investments. Total debt stood at $8.32M, with net debt of $-6.36M. The Debt-to-Equity (D/E) ratio was 0.17 (conservative).

Current ratio is 2.51, indicating strong short-term liquidity. Interest coverage is -4.6x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (28/100) — Total assets $82.35M and equity $48.23M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.17 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.

IMGN

ImmunoGen, Inc.

$31.24

+0.02%

CDTX

Cidara Therapeutics, Inc.

$221.38

+0.00%

CRVS

Corvus Pharmaceuticals, Inc.

$15.11

-0.92%

IOVA

Iovance Biotherapeutics, Inc.

$3.82

+4.95%

LIFE

aTyr Pharma, Inc.

$14.77

+0.54%

LXRX

Lexicon Pharmaceuticals, Inc.

$1.86

+6.29%

SLS

SELLAS Life Sciences Group, Inc.

$4.91

+1.03%

GNFT

Genfit S.A.

$8.95

+4.07%